UPDATE : Saturday, February 22, 2020
SillaJen shareholders panic over exec’s selling of 160,000 stocks by Jeong Sae-im 2019-07-09 11:45
Kolon TissueGene’s ₩490 billion shares on verge of becoming worthless by Jeong Sae-im 2019-07-08 12:06
Dong-A ST, Dongwha Pharm lose status of innovative drugmaker by Jeong Sae-im 2019-07-05 16:00
Victims question Kolon CEO’s sincerity in apology by Jeong Sae-im 2019-07-05 15:14
Janssen nixes deal with Hanmi over antidiabetic obesity drug by Jeong Sae-im 2019-07-04 10:52
[News Focus]Yuhan pulled off $3.1 billion licensing deals in one year. How? by Jeong Sae-im 2019-07-02 12:11
[Special]Korean drugmakers harbor undue expectations on global blockbusters by Jeong Sae-im 2019-07-01 16:19
BNO BIO to invest $1 million in Israeli biotech venture by Jeong Sae-im 2019-06-28 16:10
Shareholders in shock over HLB’s phase-3 trial setback by Jeong Sae-im 2019-06-28 10:47
‘Food and drug ministry alone can’t handle Invossa debacle’ by Jeong Sae-im 2019-06-27 12:45
Patients with ‘Invossa stigma’ struggle to get treatment, insurance by Jeong Sae-im 2019-06-26 13:22
Oscotech wins exception policy for continued R&D for new drugs by Jeong Sae-im 2019-06-25 14:11
‘Customized strategies needed for fast-changing Chinese drug regulation’ by Jeong Sae-im 2019-06-21 14:12
Despite regulator’s ruling delay, Kolon TissueGene likely to be reviewed for delisting by Jeong Sae-im 2019-06-20 14:20
‘Yuhan’s Lazertinib promising as 1st-line therapy for NSCLC’ by Jeong Sae-im 2019-06-18 14:43
Korea can benchmark Philadelphia’s rise as ‘Cellicon Valley’: experts by Jeong Sae-im 2019-06-18 13:42
Korean biosimilars take on original drugs in Europe by Jeong Sae-im 2019-06-17 15:26
294 shareholders file suit against Kolon TissueGene for damage compensation by Jeong Sae-im 2019-06-14 10:51
‘Many drugs won Chinese approval without review suspension’ by Jeong Sae-im 2019-06-13 11:26
Daewoong’s botulinum toxin hits a snag in European approval by Jeong Sae-im 2019-06-12 16:50
Back to Top